Figure 1. Chromatography process variability starts with buffer or solution make-up; effects of that variability ripple through the entire process.Some manufacturers have used over-sized equipment, processing an entire batch as one lot to minimize variability within a manufacturing campaign. However, this increases the capital required for both equipment and liquid chromatography resin. It also increases risk, since the manufacturer must, in effect, put all of its eggs in one basket. It also requires larger, heavier equipment that is more difficult for operating staff to handle. Finally, this approach eliminates the opportunity for gaining improved process knowledge from multiple runs."Blending as Usual" Falls ShortConsider some representative automated blending approaches (Figures 2 and 3) that are widely used today. At first glance, both appear seductively simple and self-explanatory. However, neither approach addresses the variability inherent in concentrated reagent feedstocks today, which typically ranges from 2-5%.
Figure 4. The accuracy and precise composition of the mobile phase has a major impact on full-scale liquid chromatography separations.By applying adaptive PAT- based blending to the creation of 0.1% accurate and reproducible mobile phase blends, it is possible to transform the process as shown in Figure 4. Besides eliminating several "hidden factory" elements, such as the need for a tank farm, excessive quality control testing and pooling and rework of product fractions, the increased resolution and reduced process noise permits a much clearer view of the underpinning process that is so essential for improved process understanding and control.By programming the liquid chromatography system not to release mobile phase to the column until it is in spec, failure from a myriad of potential causes is prevented. Adaptive control thus enables the most precise and cost-effective resolution of product and prevents product loss, which, for biopharmaceuticals, can be considerable. Furthermore, using this system during process development can permit meaningful parametric optimization, seamless technology transfer and predictable process scale-up.The Bottom LineThe economic impact of using adaptive PAT has been quantified using actual manufacturing data from a high-value pharmaceutical product (Table I). The study used a conservative first-order estimate of the benefits of the improvements recognized by FMEA (failure mode and effect analysis). It found that using an isocratic or step-gradient approach to separate closely related species, rather than an accurate linear gradient, could easily reduce first-pass recovery to below 70%. Pooling and re-working the fractions containing the remaining 30%, assuming similar recovery efficiency, yielded a total of 91% recovery.In contrast, with adaptive PAT, first-pass recovery was 90% or higher. After reprocessing the side-cuts, total recovery increased to 99%. Reduction in variability translated into savings of $16 million per year.In this particular case, the assay samples taken throughout the manufacturing process represented a full 10% of the total drug produced. This $20 million loss of product represents yet another hidden cost of the traditional quality control-based approach to making drugs. With savings like these, it's clear that adaptive PAT controls make sound business sense. Table. Liquid Chromatography Cost Savings
Product Produced |
|
200g/year at $1 million per gram | $200 million |
(25 runs of 8g per year) |
|
The |
|
(Using popular inaccurate gradient model) |
|
| $250,000 |
| $100,000 |
| $100,000 |
| $75,000 |
| $500,000 |
| $18,000,000 |
(70% recovery per run with 1 reprocessing results in 9% product loss) |
With Adaptive PAT: Operational Cost Reduction
(With ideal accurate-gradient model)
- Labor (less 1 operator)
$75,000
- QC lab (reduce testing by 10x)
$90,000
- Reduced product consumption during QC
$450,000
(10 fractions reduced to 1 fraction)